Patent Application
20180265558
This relates to the field of human growth factors and, more particularly, to making growth factors safer for human therapeutic use.
The application contains a Sequence Listing electronically submitted via EFS-web to the United States Patent and Trademark Office as a text file named “Sequence_Listing.txt.” The electronically filed Sequence Listing serves as both the paper copy required by 37 C.F.R. § 1.821(c) and the computer readable file required by 37 C.F.R. § 1.821(c). The information contained in the Sequence Listing is incorporated by reference herein in its entirety.
Insufficient blood flow is the source of a number of diseases and other physiological conditions. These include peripheral artery disease and conditions that cause skin lesions such as diabetic ulcers and bed sores.
Insufficient blood flow may be treated with a growth factor because growth factors promote new blood vessel growth and regeneration of tissue. Several growth factors have been evaluated in both pre-clinical and clinical studies. Such growth factors include vascular endothelial cell growth factor (VEGF), platelet derived growth factor (PDGF), fibroblast growth factor 1 and 2 (FGF-1 and FGF-2), and keratinocyte growth factor (KGF).
A drawback to using one or more of these growth factors is that they have poor pharmacokinetic profiles. They have a fast clearance rate from the body after administration, resulting in the need for frequent and repetitive dosing. They also distribute throughout the body after administration, which may cause undesirable side-effects.
An important safety concern for using growth factors is to minimize their systemic distribution to prevent negative off-target effects. When administered, growth factors can diffuse into the circulatory system, travel throughout the body, and stimulate the growth of cancer cells that might exist far from the site where the growth factor was administered.
A pharmacokinetic study from 2012 showed that wild-type FGF-1 binds to heparin. According to that study, the pharmacokinetic profile of FGF-1 is predominantly determined by the binding affinity of FGF-1 to heparan sulfate glycosaminoglycan (HSGAG), which is also known as heparan sulfate proteoglycan (HSPG). HSGAG is a sulfated or acetylated polysaccharide located on the surface of different cells and tissues, such as vascular endothelial cells of the liver and kidney. See, X. Xia, et al., “Pharmacokinetic properties of 2nd-generation fibroblast growth factor-1 mutants for therapeutic application.” PLoS ONE 7(11): e48210 2012.
It would be advantageous to improve the binding affinity of FGF-1 to heparin to improve the likelihood that FGF-1 will substantially remain at the site of administration rather than distributing throughout the body. The problem of increasing FGF-1's binding affinity to heparin is solved by modifying the polypeptide sequence of FGF-1 to have an increased binding affinity for heparin relative to the binding affinity of wild-type FGF-1 to heparin.
In an example of a composition aspect, the composition comprises a modified FGF-1 polypeptide having at least 80% amino acid sequence identity to wild-type human FGF-1 having SEQ ID NO: 1. The serine at an amino acid position of the modified FGF-1 polypeptide corresponding to amino acid position 116 of SEQ ID NO: 1 is substituted by an amino acid that increases the modified FGF-1 polypeptide's binding affinity for heparin relative to the binding affinity of SEQ ID NO: 1 to heparin.
In an example of a first method aspect, the method comprises increasing the binding affinity to heparin of wild-type human FGF-1 having SEQ ID NO: 1 by forming a modified FGF-1 polypeptide having at least 80% amino acid sequence identity to SEQ ID NO: 1. The serine at an amino acid position of the modified FGF-1 polypeptide corresponding to amino acid position 116 of SEQ ID NO: 1 is an amino acid that increases the modified FGF-1 polypeptide's binding affinity for heparin relative to the binding affinity of SEQ ID NO: 1 to heparin.
In an example of a second method aspect, a method of treating a physiological condition associated with insufficient blood flow comprises administering to a subject in need thereof a composition comprising a therapeutically effective amount of a modified FGF-1 polypeptide having at least 80% amino acid sequence identity to wild-type human FGF-1 having SEQ ID NO: 1. The serine at an amino acid position of the modified FGF-1 polypeptide corresponding to amino acid position 116 of SEQ ID NO: 1 is substituted by an amino acid that increases the modified FGF-1 polypeptide's binding affinity for heparin relative to the binding affinity of SEQ ID NO: 1 to heparin.
In an example of a third method aspect, a method of treating a wound comprises administering to a human subject having a wound a composition comprising a therapeutically effective amount of a modified FGF-1 polypeptide having at least 80% amino acid sequence identity to wild-type human FGF-1 having SEQ ID NO: 1. The serine at an amino acid position of the modified FGF-1 polypeptide corresponding to amino acid position 116 of SEQ ID NO: 1 is substituted by an amino acid that increases the modified FGF-1 polypeptide's binding affinity for heparin relative to the binding affinity of SEQ ID NO: 1 to heparin.
In the compositions and methods, the modified FGF-1 polypeptide may comprise SEQ ID NO: 2 or consist of SEQ ID NO: 2.
In the compositions and methods, the modified FGF-1 polypeptide may comprises SEQ ID NO: 3 or consist of SEQ ID NO: 3.
In the compositions and methods, the amino acid that increases the modified FGF-1 polypeptide's binding affinity for heparin may be arginine.
In the compositions and methods, the amino acid that increases the modified FGF-1 polypeptide's binding affinity for heparin may be lysine.
In the compositions and methods, the modified FGF-1 polypeptide may have at least 90% amino acid sequence identity to wild-type human FGF-1 having SEQ ID NO: 1 and/or it may have at least 99% amino acid sequence identity to wild-type human FGF-1 having SEQ ID NO: 1.
Modifications may be made to wild type human FGF-1 to increase its binding affinity for heparin. Because the modified FGF-1 has a higher binding affinity for heparin than wild-type FGF-1, using modified FGF-1 in a therapeutic treatment can lower the systemic distribution of FGF-1. This means that when modified FGF-1 is administered to a portion of the body, it is more likely to remain at that portion of the body because it is bound to heparin. This increases the mean residence time of FGF-1 at the desired location, thereby improving the efficacy of FGF-1 and decreasing the dosage level or the need to re-administer FGF-1 to achieve efficacy.
The term “binding affinity” refers, for example, to how strong a polypeptide's binding activity is for a particular target such as heparin. There are many ways to quantify the binding affinity of a polypeptide to heparin. Examples include, but are not limited to, thermodynamic techniques such as isothermal titration calorimetry.
The term “heparin” refers, for example, to heparin, heparan sulfate, heparan sulfate proteoglycan, and heparan sulfate glycosaminoglycan.
Other forms of FGF-1, such as the 155 amino acid form, include SEQ ID NO: 1. The 140 amino acid form is produced by proteolysis of the 155 amino acid form. The 155 amino acid form is in
There is also a 154 amino acid form that differs from the 155 amino acid form by deleting methionine at position 1 of the 155 amino acid form. When FGF-1 is purified from natural tissue, the 154 and 140 amino acid forms are present. The methionine at position 1 is removed. The numbering scheme for the 154 amino acid form is simply shifted by 1 to account for the removed methionine.
As shown in
Examples of compositions that include a modified FGF-1 polypeptide with increased binding affinity to heparin will now described.
The composition generally includes a modified FGF-1 polypeptide having at least 80% amino acid sequence identity to wild-type human FGF-1 having SEQ ID NO: 1. The serine at an amino acid position of the modified FGF-1 polypeptide corresponding to amino acid position 116 of SEQ ID NO: 1 is substituted by an amino acid that increases the modified FGF-1 polypeptide's binding affinity for heparin relative to the binding affinity of SEQ ID NO: 1 to heparin.
Examples of amino acids that increase the modified FGF-1 polypeptide's binding affinity for heparin relative to the binding affinity of SEQ ID NO: 1 to heparin include arginine (Arg) and lysine (Lys).
A particular example of the modified FGF-1 polypeptide is in
Another particular example of the modified FGF-1 polypeptide is in
The modified FGF-1 polypeptide does not need not have such close amino acid sequence identity with SEQ ID NO: 1 as SEQ ID NOS: 2 and 3 have, so long as the mitogenic function of SEQ ID NO: 1 is preserved in the modified FGF-1.
Having at least 80% amino acid sequence identity to wild-type human FGF-1 means that at least 80% of the amino acid residues of multiple polypeptides being compared to each other have the same amino acid at the corresponding position on the other polypeptide. For example, a polypeptide that has least 80% amino acid sequence identity to another polypeptide sequence has at least 80% of its amino acid residues at the corresponding position on the other polypeptide.
In another example, the modified FGF-1 polypeptide has at least 90% amino acid sequence identity to wild-type human FGF-1. This means that at least 90% of the amino acid residues of multiple polypeptides being compared to each other have the same amino acid at the corresponding position on the other polypeptide. For example, a polypeptide that has least 90% amino acid sequence identity to another polypeptide sequence has at least 90% of its amino acid residues at the corresponding position on the other polypeptide.
In an additional example, the modified FGF-1 polypeptide has at least 99% amino acid sequence identity to wild-type human FGF-1. This means that at least 99% of the amino acid residues of multiple polypeptides being compared to each other have the same amino acid at the corresponding position on the other polypeptide. For example, a polypeptide that has least 99% amino acid sequence identity to another polypeptide sequence has at least 99% of its amino acid residues at the corresponding position on the other polypeptide.
In these examples of the modified FGF-1 polypeptide, an amino acid residue at a particular position on one polypeptide does not have to be at exactly the same position on another polypeptide to qualify as being at a “corresponding” position. Different polypeptides may have different amino acid positions and numbering schemes, depending on how similar the polypeptides are. Different polypeptides may have different lengths, insertions, mutations, substitutions, and/or deletions, which would offset the amino acid numbering scheme. Amino acid positions on different polypeptides may correspond to each other if the amino acid positions are similar when compared to their tertiary structures. A skilled artisan can determine whether amino acid positions on different polypeptides correspond to each other based on their primary and/or tertiary structures.
The modification to the FGF-1 polypeptide at Ser116 may be a gain-of-function mutation that enhances the mitogenic activity of the modified FGF-1 polypeptide relative to the mitogenic activity of the wild-type human FGF-1 polypeptide. This gain-of-function may or may not be associated with increased heparin binding affinity.
The modified FGF-1 polypeptide may include the modification at Ser116 or a corresponding position in combination with one or more additional modifications. For example, other amino acids may be substituted to stabilize the modified FGF-1 and/or to remove the free cysteine residues.
The modified FGF-1 polypeptide may be an active ingredient in a pharmaceutical composition. In such a case, the modified FGF-1 polypeptide may be blended with one or more pharmaceutically acceptable excipients useful for making the composition into a pharmaceutically acceptable dosage form.
Exemplary excipients include, but are not limited to, carriers, diluents, disintegrants, emulsifiers, solvents, processing aids, buffering agents, colorants, flavorings, solvents, coating agents, binders, carriers, glidants, lubricants, granulating agents, gelling agents, polishing agents, suspending agent, sweetening agent, anti-adherents, preservatives, emulsifiers, antioxidants, plasticizers, surfactants, viscosity agents, enteric agents, wetting agents, thickening agents, stabilizing agents, solubilizing agents, bioadhesives, film forming agents, emollients, dissolution enhancers, dispersing agents, or combinations thereof.
Since the pharmaceutical composition, includes a polypeptide, the pharmaceutical composition may include at least one substance that substantially inhibits protein degradation.
The pharmaceutical composition, may include one or more additional growth factors and/or angiogenic compounds, such as, for example, VEGF, PDGF, KGF, other wild-type and/or mutant YGF proteins, and vasodilators.
In the pharmaceutical composition, the modified FGF-1 polypeptide is present in a therapeutically effective amount. A therapeutically effective amount is an amount effect achieve desired therapeutic benefit, such as an amount effective prevent, alleviate, ameliorate, or treat the underlying causes and/or symptoms of the physiological condition being treated.
For some uses of the pharmaceutical composition, a therapeutically effective amount is an amount effective to increase blood flow, stimulate angH and/or vascularization within or to a particular tissue or region of the body of a treatment subject. The degree to which blood flow, angiogenesis, and/or vascularization increased within a region of body may be determined by conventional pathological or clinical techniques, such as imaging techniques using a contrast dye to detect vasculature or the reduction of symptoms associated with an underlying disorder.
For some uses of the pharmaceutical composition, therapeutically effective amount may be an amount effective improve the quality and/or rate of healing or repair of a damaged tissue or wound. The improvement is quantifiable according to conventional clinical practices.
When the pharmaceutical composition is administered to cardiac tissue, therapeutically effective amount may be an amount effective reduce clinical symptoms of peripheral artery disease, such as reduction in angina, breathlessness, leg heart or respiratory rates, edema, fatigue, or weakness, or to reduce the risk of a myocardial infarction.
In humans, a therapeutically effective amount range is often 1-1,000 mg/day, including 1-25 mg/day, 25-50 mg/day, 50-75 mg/day, 75-100 mg/day, 100-150 mg/day, 150-200 mg/day, 200-250 mg/day, 250-300 mg/day, 300-350 mg/day, 350-400 mg/day, 400-450 mg/day, 450-500 mg/day, 500-550 mg/day, 550-600 mg/day, 600-650 mg/day, 650-700 mg/day, 700-750 mg/day, 750-800 mg/day, 800-850 mg/day, 850-900 mg/day, 900-950 mg/day, 950-1,000 mg/day. Higher doses (1,000-3,000 mg/day) might also be effective. The weight in mg is often calibrated to the body weight of the subject in kg, thus these example doses may also be written in terms of mg/kg of body weight per day.
In practice, the therapeutically effective amount may vary depending on numerous factors associated with the treatment subject, including age, weight, height, severity of the disorder, administration technique, and other factors. The therapeutically effective amount of the modified FGF-1 polypeptide administered to a given subject may be determined by medical personnel taking into account the relevant circumstances.
The therapeutically effective amount may be determined or predicted from empirical evidence. Specific dosages may vary according to numerous factors and may be initially determined on the basis of in vitro, cell culture, and/or animal in vivo studies. Dosages or concentrations tested in vitro for modified FGF-1 polypeptides may provide useful guidance in determining therapeutically effective and appropriate amounts for administration.
The pharmaceutical composition may be administered as a single dose or as part of a dosage regimen. For a dosage regimen, the therapeutically effective amount is adjustable dose to dose to provide a desired therapeutic response.
Multiple doses may be administered at a predetermined time interval and subsequent may be proportionally reduced, depending on the situation. By administering the pharmaceutical composition as part of a dosage regimen, local concentrations may be allowed to reach a desired concentration for a modified FGF-1 over a series of doses.
As mentioned above, the modified FGF-1 polypeptide increases the binding affinity to heparin of wild-type human FGF-1 having SEQ ID NO: 1. This is achieved by forming a modified FGF-1 polypeptide having at least 80% amino acid sequence identity to SEQ ID NO: 1 where the serine at an amino acid position of the modified FGF-1 polypeptide corresponding to amino acid position 116 of SEQ ID NO: 1 is an amino acid that increases the modified FGF-1 polypeptide's binding affinity for heparin relative to the binding affinity of SEQ ID NO: 1 to heparin.
The modified FGF-1 polypeptide can be formed using conventional protein synthesis techniques such as liquid-phase synthesis, solid-phase synthesis, and/or by recombinant expression and purification. The expression and purification technique involves obtaining artificial genes with the desired nucleic acid sequence for expressing the synthetic polypeptide with the desired polypeptide sequence. Expression of the synthetic protein may be performed by bacteria cells. The cells are subsequently lysed and the synthetic protein is purified from the lysed cells.
The modified FGF-1 may be used to treat a physiological condition associated with insufficient blood flow. An example of a method of treating a physiological condition associated with insufficient blood flow includes administering to a subject in need thereof a composition comprising a therapeutically effective amount of a modified FGF-1 polypeptide having at least 80% amino acid sequence identity to wild-type human FGF-1 having SEQ ID NO: 1. The serine at an amino acid position of the modified FGF-1 polypeptide corresponding to amino acid position 116 of SEQ ID NO: 1 is substituted by an amino acid that increases the modified FGF-1 polypeptide's binding affinity for heparin relative to the binding affinity of SEQ ID NO: 1 to heparin.
The physiological condition associated with insufficient blood flow may be, for example, ischemia, hypoxia, peripheral artery disease, coronary artery disease, skin lesions, wounds, vascular occlusion, vascular disease, and/or avascular necrosis.
The subject may be a human or animal subject.
The pharmaceutical composition may be administered via a number of techniques. The selection of the administration technique depends on the specific area to be treated and whether local or systemic treatment is preferred. Administration techniques include, for example, enteral, parenteral, topical, or local administration techniques.
Enteral routes for administration include, example, oral, rectal, intestinal, and gastric routes.
Parenteral routes for administration include, for example, intravenous, transmucosal, inhalation, intracranial intraocular, intrathecal, intraperitoneal, subcutaneous, intramuscular, and intradermal routes.
Some administration techniques involve administering the pharmaceutical composition as unit dosage form. For example, unit dosage forms suitable for oral administration include solid dosage forms, such as powders, granules, tablets, pills, capsules, suppositories, and sachets. They also include liquid dosage forms, such as elixirs, syrups, suspensions, sprays, gels, lotions, creams, foams, ointments, salves, solutions, tinctures, and emulsions.
The pharmaceutical composition may be administered either locally or systemically. Examples of local delivery routes include, for example, parenteral administration, local injection, or topical application at or near a sine of the body to be treated. That site may be associated with a disorder or disease, such as a site afflicted with ischemia or a site of an injury or wound.
A pharmaceutical composition parenteral administration may be formulated as a solution, emulsion, suspension, or other liquid, such as saline, dextrose solution, glycerol, and the like.
The pharmaceutical composition may be administered by local injection, placement, catheter, or implantation at the desired site of in the body of the treatment subject.
The pharmaceutical composition may be administered topically, such as at a site of a tissue injury or a wound.
The topical administration technique may include polymer matrix that controls the release of the modified FGF-1 polypeptide at the site of administration.
Cells may be grown outside the body for use in transplantation, to a treatment subject. Culturing cells ex vivo may allow for their expansion and/or manipulation prior to use. A modified FGF-1 polypeptide may be introduced to the cell culture to improve the proliferation of the cells.
This section provides specific examples of the composition and method aspects. The scope of the possible aspects and embodiments is not limited to what these examples teach.
A codon-optimized synthetic gene encoding 140 amino acids form of human FGF-1 (SEQ ID NO: 1) with an N-terminal six His tag was cloned into the pET21a (+) expression vector. The His tag has shown no influence upon stability, heparin affinity and mitogenic activity. Residue Ser116 inside of the heparin binding site of FGF-1 was mutated to Arginine (SEQ ID NO: 2) and Lysine (SEQ ID NO: 3) individually to increase potential ionic interactions with the sulfonate groups in HSGAG. This was achieved using a QUICKCHANGE site-directed mutagenesis protocol.
Each mutation was confirmed by DNA sequencing. The pET21a (+)/BL21(DE3) E. coli host expression system was used to express the FGF-1 heparin affinity mutants. The expressed polypeptide was purified via sequential nickel-nitrilotriacetic acid (Ni-NTA) column (Qiagen) and heparin Sepharose resin (GE Life Sciences, Pittsburgh Pa.). Previous studies of wild-type FGF-1 have shown that the above purification procedure results in protein >99% pure and appropriate for all biophysical studies.
Heparin Affinity Study with Isothermal Titration Calorimetry (ITC)
Purified modified FGF-1 samples of SEQ ID NOs: 2 and 3 were dialyzed into 20 mM N-(2-acetamido) iminodiacetic acid (ADA), 100 mM NaCl, pH 7.4 for an ITC study. An iTC200 microcalorimeter (MicroCal) was used for data collection. Each modified FGF-1 sample had a polypeptide concentration of 60 μM and was titrated with 750 μM sucrose octasulfate. The ITC running parameters were: 31 injections; first injection volume 0.5 μl and the rest of the injections 1 μl; temperature 25° C.; reference power 5. The titration curve after baseline subtraction was fitted with a single ligand-binding site model by manufacturer's software (MicroCal Origin). At least three independent trials were collected for each modified FGF-1 samples.
Table 1 shows the quantification of the affinity between FGF-1 wild-type and the modified FGF-1 samples and sucrose octasulfate (HSGAG analog) by ITC.
1 The titration curves were fitted using the manufacture's software (MicroCal Origin)with a single ligand-binding site model
2 Kd is dissociation constant. The smaller value indicates the higher affinity.
The single mutation Ser116Arg or Ser116Lys in FGF-1 increased the affinity of FGF-1 towards HSGAG.
Based on the previous pharmacokinetic study, the FGF-1 binding affinity to heparin/HSGAG is a key determinant of the distribution and elimination kinetics in the pharmacokinetic profile. Therefore, the Ser116Arg or Ser116Lys mutants may have an altered pharmacokinetic profile: a shorter distribution half-life, a longer elimination half-life and a longer mean residence time, relative to wild-type FGF-1.
The changes in pharmacokinetic profile of the Ser116Arg and Ser116Lys mutants may result in increased therapeutic efficacy by prolonging the duration of the modified FGF-1 polypeptides inside the body.
A BaF3 cell system expressing FGFR-1c was used to quantify receptor activation by wild-type FGF-1. The BaF3 cells lack membrane-bound HS proteoglycan. Heparan sulfate was added to the assay to promote the ternary FGF/FGFR/HS signal transduction complex. Cells were maintained in RPMI 1640 media (Sigma Chemical, St. Louis Mo.) supplemented with 10% newborn bovine serum (Sigma Chemical, St. Louis Mo.), 0.5 ng/mL murine recombinant interleukin-3 (mIL-3, PeproTech Inc, Rocky Hill N.J.), mM L-glutamine, penicillin-streptomycin and 50 μM β-mercaptoethanol (“BaF3 culture medium”), and G418 (600 μg/mL). FGFR-1c expressing BaF3 cells were washed twice in BaF3 “assay media” (“culture media” lacking mIL-3) and plated at a density of 30,000 cells per well in a 96-well assay plate in assay media containing heparin (1 μg/mL). Concentrations of recombinant wild-type FGF-1 and modified FGF-1 (S116R mutant protein) ranged from 0.02 to 5 nM (3.18×102-7.95×104 μg/mL). The cells were incubated for 36 hours and mitogenic activity was determined by adding 1 μCi of 3H-thymidine in 50 μl of BaF3 assay medium to each well. Cells were harvested after 4 hours by filtration through glass fiber paper. Incorporated 3H-thymidine was counted on a Wallac β plate scintillation counter (PerkinElmer, Waltham Mass.).
The mitogenic activity of wild-type FGF-1 and S116R towards NIH 3T3 fibroblasts was studied. In contrast to BaF3 cells, NIH 3T3 fibroblast cells do express HS proteoglycan, thus, no heparan sulfate was added in this assay.
NIH 3T3 fibroblasts were initially plated in Dulbecco's modified Eagle's medium (DMEM) (American Type Culture Collection, Manassas Va.) supplemented with 10% (v/v) newborn calf serum (NCS) (Sigma, St. Louis Mo.), 100 units of penicillin, 100 mg of streptomycin, 0.25 mg of Fungizone and 0.01 mg/mL of gentamicin (Gibco, Carlsbad Calif.) (serum-rich medium) in T75 tissue culture flasks (Fisher, Pittsburgh Pa.). The cultures were incubated at 37° C. with 5% (v/v) CO2 supplementation. At ˜80% cell confluence, the cells were washed with 5 mL of TBS (0.14 M NaCl, 5.1 mM KCl, 0.7 mM Na2HPO4, 24.8 mM Trizma base (pH 7.4)) and subsequently treated with 5 mL of a 0.025% (v/v) trypsin solution (Invitrogen Corp., Carlsbad Calif.).
The trypsinized cells were then seeded in T25 tissue culture flasks at a density of 3×104 cells/cm2 (representing ˜20% confluence). Cell quiescence was initiated by serum starvation in DMEM with 0.5% NCS, 100 units of penicillin, 100 mg of streptomycin, 0.25 mg of Fungizone and 0.01 mg/mL of gentamicin. Cultures were incubated for 48 hours at 37° C., the medium was then decanted and replaced with fresh medium supplemented with wild-type or S116R FGF-1 protein from 0.063 to 630 nM (1×103-1×107 μg/mL), and the cultures incubated for an additional 48 hours.
After this incubation, the medium was decanted and the cells were washed with 1 mL of TBS. Then 1 mL of 0.025% trypsin was then added to release the cells from the flask surface, and 2 mL of serum-rich medium was added to dilute and inhibit the trypsin. Triplicate cell samples were counted using a Coulter Counter (Beckman Coulter, Brea Calif.). Dose response experiments were performed in quadruplicate, and the cell counts were averaged and normalized to a % maximal stimulation in reference to 10% NCS stimulation.
The mitogenic response of BaF3 cells expressing FGFR-1c towards wild-type FGF-1 and S116R mutant (in the presence of added heparin in the assay) is shown in
The S116R mutant exhibited an increase in mitogenic activity in comparison to wild-type FGF-1 over the range of approximately 3-4 log μg/mL. The S116R mutant exhibited about 10 times greater mitogenic potency, on an equivalent concentration basis, compared to wild type FGF-1.
The mitogenic activity of WT FGF-1 and S116R towards NIH 3T3 fibroblasts (in the absence of exogenously added heparin in the assay) is shown in
The BaF3/FGFR-1c and NIH 3T3 assays of mitogenic activity indicated an about 10-fold increase in mitogenic activity for S116R, identifying S116R as a gain-of-function mutation.
This disclosure describes preferred embodiments, but not all possible embodiments of the compositions and methods. Where a particular feature is disclosed in the context of a particular composition or method, that feature can also be used, to the extent possible, in combination with and/or in the context of other embodiments of the compositions and methods. The compositions and methods may, be embodied in many different forms and should not be construed as limited to only the embodiments described here.
This claims priority from U.S. provisional Application No. 62/086,788, filed Dec. 3, 2014, which is incorporated by reference in its entirety.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US15/63333 | 12/2/2015 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 62086788 | Dec 2014 | US |
